New hope for patients with aggressive cancers that have run out of options
NCT ID NCT05205330
Summary
This study is testing the safety and effectiveness of a new two-drug combination for people with advanced colorectal and other gastrointestinal cancers that have stopped responding to standard treatments. The trial combines an oral pill (vorbipiprant) with an immunotherapy drug (balstilimab) to see if they can help control the cancer. It is for patients who have already tried at least two other treatments and have very limited options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, 56126, Italy
-
Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
Istituto Oncologico Veneto IRCCS
Padua, Padova, 35128, Italy
Conditions
Explore the condition pages connected to this study.